Genelux Common Stock In The News
| GNLX Stock | 3.08 0.05 1.65% |
Our overall analysis of Genelux Common's news coverage and content from conventional and social sources shows investors' bearish mood towards Genelux Common. The specific impact of Genelux Common news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Genelux Common's overall financial health and prospects. It also depends on the type and quality of a news publisher.
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Genelux Common headlines in addition to utilizing other, more conventional financial analysis modules. Check out Genelux Common Backtesting and Genelux Common Hype Analysis. For more information on how to buy Genelux Stock please use our How to Invest in Genelux Common guide.
Genelux |
Genelux Common Today Top News and Investor Outlook
Genelux Common Past News Timeline
Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Genelux and other traded companies coverage with news coverage. We help investors stay connected with Genelux headlines for the 30th of March to make an informed investment decision based on correlating the impacts of news items on Genelux Stock performance. Please note that trading solely based on the Genelux Common hype is not for everyone as timely availability and quick action are needed to avoid losses.
Genelux Common stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Genelux earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Genelux Common that are available to investors today. That information is available publicly through Genelux media outlets and privately through word of mouth or via Genelux internal channels. However, regardless of the origin, that massive amount of Genelux data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Genelux Common news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Genelux Common relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Genelux Common's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Genelux Common alpha.
Genelux Largest EPS Surprises
Earnings surprises can significantly impact Genelux Common's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-11-14 | 2023-09-30 | -0.18 | -0.2 | -0.02 | 11 | ||
2024-05-09 | 2024-03-31 | -0.23 | -0.29 | -0.06 | 26 | ||
2024-03-29 | 2023-12-31 | -0.19 | -0.25 | -0.06 | 31 | ||
2023-08-14 | 2023-06-30 | -0.15 | -0.23 | -0.08 | 53 | ||
2023-05-15 | 2023-03-31 | -0.16 | -0.53 | -0.37 | 231 |
Genelux Common Stock Latest Headlines
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Genelux Common Stock. Current markets are strongly bearish. About 72% of major world exchanges and indexes are down. See today's market update for more information.
28th of March 2025
Genelux GAAP EPS of -0.95 misses by 0.07 at seekingalpha.com
28th of March 2025
Inventiva SA Earnings Call Highlights Navigating Financial Challenges and ... - Yahoo Fina... at news.google.com
27th of March 2025
Dyadic International Inc Q4 2024 Earnings Call Highlights Revenue Growth and Strategic ... at gurufocus.com
25th of March 2025
Genelux Corporation Announces Pricing of 10.5 Million Underwritten Offering of Common Stoc... at finance.yahoo.com
25th of March 2025
Disposition of 10000 shares by Weinhoff Gregory M of Centessa Pharmaceuticals at 3.85 subj... at thelincolnianonline.com
24th of March 2025
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter an... at globenewswire.com
24th of March 2025
Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and... at globenewswire.com
21st of March 2025
Acquisition by Thomas John of 50469 shares of Genelux Common at 1.96 subject to Rule 16b-3 at Thomas John
20th of March 2025
Terns Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Corp... at globenewswire.com
20th of March 2025
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corpo... at finance.yahoo.com
20th of March 2025
Immuneering Names Dr. Igor Matushansky as Chief Medical Officer at gurufocus.com
19th of March 2025
Short Interest in Dyadic International, Inc. Declines By 19.9 at thelincolnianonline.com
19th of March 2025
Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formul... at finance.yahoo.com
17th of March 2025
Insider Trading at MacroaxisInsider
14th of March 2025
Acquisition by Lu Hongbo of 4676 shares of Terns Pharmaceuticals at 6.85 subject to Rule 1... at MacroaxisInsider
14th of March 2025
Disposition of 541897 shares by Versant Venture Capital Vi, L.p. of Monte Rosa at 6.0 subj... at thelincolnianonline.com
14th of March 2025
Disposition of 964 shares by Zhang Xiaoyan Michelle of Ikena Oncology at 12.0 subject to R... at MacroaxisInsider
12th of March 2025
Acumen Pharmaceuticals to Present During International Conference on Alzheimers and Parkin... at globenewswire.com
7th of March 2025
Brokerages Set Celcuity Inc. Target Price at 30.17 - Defense World at news.google.com
6th of March 2025
JPMorgan Chase Co. Lowers Day One Biopharmaceuticals Price Target to 34.00 - Defense World at news.google.com
6th of March 2025
Can Amylyx Shape the Future of Biotech at kalkinemedia.com
6th of March 2025
Molecular Glues Competitive Landscape 2025 Exploring 65 Drugs and 50 Biotech Players in th... at globenewswire.com
6th of March 2025
Newamsterdam pharma director James Topper buys 84,203 in shares - Investing.com at news.google.com
6th of March 2025
Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750... at gurufocus.com
5th of March 2025
Amylyx Pharmaceuticals, Inc. Q4 2024 Earnings Call Transcript at insidermonkey.com
4th of March 2025
Acquisition by Lucy Patrick K. of 23585 shares of Dyadic International subject to Rule 16b... at MacroaxisInsider
4th of March 2025
Cingulate Reports Safety Results from Final Phase 3 Trials for Lead ADHD Asset CTx-1301 On... at globenewswire.com
3rd of March 2025
Disposition of 1611 shares by Gina Mazzariello of Amylyx Pharmaceuticals at 3.1175 subject... at finance.yahoo.com
3rd of March 2025
Cullinan Oncology stock hits 52-week low at 8.35 - Investing.com at news.google.com
28th of February 2025
What is Wedbushs Forecast for DAWN Q1 Earnings at thelincolnianonline.com
28th of February 2025
NewAmsterdam Pharma Announces Quarterly Earnings Results at thelincolnianonline.com
27th of February 2025
Needham Company LLC Increases MoonLake Immunotherapeutics Price Target to 66.00 at thelincolnianonline.com
27th of February 2025
Cullinan Therapeutics Is In A Good Position To Deliver On Growth Plans at simplywall.st
26th of February 2025
Insider Trading at MacroaxisInsider
25th of February 2025
Terns Pharmaceuticals Provides Program Updates and Announces Participation at TD Cowen 45t... at gurufocus.com
25th of February 2025
DAWN chiede alla Corte penale internazionale di indagare sullamministrazione Biden per fav... at businesswire.com
25th of February 2025
NewAmsterdam Pharma Co NV Announces Participation in Key Investor Conferences at gurufocus.com
25th of February 2025
Disposition of 3756 shares by Sumer Jacquelyn L of Cullinan Oncology at 8.53 subject to Ru... at MacroaxisInsider
21st of February 2025
Centessa Pharmaceuticals plc Short Interest Update - MarketBeat at news.google.com
20th of February 2025
BioMarin Q4 Earnings Sales Top Estimates, Stock Up on Upbeat 25 View at zacks.com
14th of February 2025
Avoro Capital Advisors LLC Reduces Stake in Monte Rosa Therapeutics Inc at gurufocus.com
14th of February 2025
Both private equity firms who control a good portion of NewAmsterdam Pharma Company N.V. a... at finance.yahoo.com
14th of February 2025
Compass Therapeutics Shares Down 7.6 percent - Should You Sell - MarketBeat at news.google.com
13th of February 2025
Is Genelux In A Good Position To Invest In Growth at simplywall.st
11th of February 2025
ABOS stock touches 52-week low at 1.31 amid market challenges - MSN at news.google.com
10th of February 2025
Compass Therapeutics, Inc. Upgraded to Buy What Does It Mean for the Stock at zacks.com
10th of February 2025
Immuneering Co. Given Consensus Recommendation of Hold by Brokerages at thelincolnianonline.com
7th of February 2025
Q2 Earnings Estimate for Celcuity Issued By Leerink Partnrs at thelincolnianonline.com
5th of February 2025
Melita Sun Jung Acquires 2,250 Shares of Terns Pharmaceuticals, Inc. Stock at thelincolnianonline.com
31st of January 2025
Acquisition by Matthew Pulisic of 275000 shares of Genelux Common at 3.95 subject to Rule ... at MacroaxisInsider
31st of January 2025
Disposition of 2533 shares by Klausner Arthur J of Monopar Therapeutics subject to Rule 16... at MacroaxisInsider
31st of January 2025
Amylyx Pharmaceuticals Upgraded to Buy What Does It Mean for the Stock at zacks.com
31st of January 2025
Cullinan Therapeutics Is In A Good Position To Deliver On Growth Plans at finance.yahoo.com
30th of January 2025
Insider Trading at Matthew Pulisic
27th of January 2025
When the Price of Talks, People Listen - Stock Traders Daily at news.google.com
27th of January 2025
Larimar Therapeutics Aligns Executive Incentives with Milestones - TipRanks at news.google.com
24th of January 2025
Cingulate Inc. adjusts executive compensation - Investing.com at news.google.com
23rd of January 2025
Immuneering Leads The Pack Of 3 US Penny Stocks To Consider at simplywall.st
21st of January 2025
Up 1,000 percent in 2024, Wall Street Believes This Growth Stock Can Still Skyrocket - Tra... at news.google.com
17th of January 2025
Acquisition by Shankar Gopi of 22500 shares of Larimar Therapeutics subject to Rule 16b-3 at MacroaxisInsider
10th of January 2025
Dyadic International Stock Price Passes Above 50 Day Moving Average - Time to Sell - Marke... at news.google.com
2nd of January 2025
Inmagene Bio charts backdoor to U.S. listing with offshore acquisition - Bamboo Works at news.google.com
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Genelux Common in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Genelux Common's short interest history, or implied volatility extrapolated from Genelux Common options trading.
Additional Tools for Genelux Stock Analysis
When running Genelux Common's price analysis, check to measure Genelux Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genelux Common is operating at the current time. Most of Genelux Common's value examination focuses on studying past and present price action to predict the probability of Genelux Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genelux Common's price. Additionally, you may evaluate how the addition of Genelux Common to your portfolios can decrease your overall portfolio volatility.